HGH (Somatropin) Research Overview (also known as 191aa Recombinant Growth Hormone)
Human Growth Hormone (HGH), also known as somatropin or somatotropin, is a 191 amino acid single-chain polypeptide hormone naturally produced by the anterior pituitary gland. Recombinant HGH (rhGH/somatropin) is bioidentical to endogenous growth hormone and is FDA-approved for growth hormone deficiency in children and adults, as well as several other conditions. The '191aa' designation refers to its complete 191 amino acid structure, distinguishing it from older 192aa formulations. HGH regulates
What Is HGH (Somatropin)?
Human Growth Hormone (HGH), also known as somatropin or somatotropin, is a 191 amino acid single-chain polypeptide hormone naturally produced by the anterior pituitary gland. Recombinant HGH (rhGH/somatropin) is bioidentical to endogenous growth hormone and is FDA-approved for growth hormone deficiency in children and adults, as well as several other conditions. The '191aa' designation refers to its complete 191 amino acid structure, distinguishing it from older 192aa formulations. HGH regulates growth, metabolism, body composition, and numerous physiological processes through direct actions and via stimulating IGF-1 production.
Mechanism of Action
Binds GH receptors, activates JAK2-STAT5 pathway. Direct effects: lipolysis, protein synthesis. Indirect effects via IGF-1: growth, cell proliferation, anabolism. Half-life ~3 hours subcutaneously.
Key Benefits
Improved body composition (fat loss, lean mass gain), enhanced bone density, better lipid profile, increased energy and recovery, improved skin/hair, better quality of life
Quick Reference
| Literature-Reported Dose Range | Start 1-2 IU daily, increase gradually |
| Literature-Reported Frequency | Once daily (morning) or split at higher doses |
| Literature-Reported Cycle Length | 3-6 months minimum; can be continuous under medical supervision |
| Literature-Reported Washout | 5 on/2 off or periodic breaks in some protocols |
| Storage | Refrigerate 2-8°C; reconstituted use within 14-28 days |
| Sites Reported in Studies | Abdomen, thigh, upper arm - rotate |
| Timing | Morning fasted for fat loss; evening mimics natural pulse |
Research Indications
Growth Hormone
Growth Hormone Deficiency
FDA-approved for pediatric GHD, adult GHD, Turner syndrome, Prader-Willi, SGA, and other conditions
HIV-Associated Wasting
FDA-approved to increase lean body mass in HIV-associated cachexia
Body Composition
Fat Mass Reduction
Consistent reduction in fat mass, especially visceral adiposity, through enhanced lipolysis
Lean Mass Increase
Statistically significant increases in lean body mass demonstrated in meta-analyses
Anti-Aging
Anti-Aging Research
Research shows body composition and recovery benefits; not FDA-approved for anti-aging
Recovery
Recovery & Performance
May support recovery and athletic performance through enhanced protein synthesis and tissue repair
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Anti-Aging / Longevity | 1–2 IU daily | Once daily | SubQ |
| Body Composition | 3–6 IU daily | Once daily | SubQ |
| Advanced Bodybuilding | 6–10+ IU daily | Once daily | SubQ |
Timing
Recommended administration window: before bedtime — aligns with the natural nocturnal GH pulse during deep sleep. For higher doses, split dosing is an option: ⅔ at night + ⅓ morning or pre-workout. Typical onset: 4–8 weeks (metabolic changes); 3–6 months (body composition). Note: doses above 8 IU/day significantly increase side-effect risk.
Administration Methods
Subcutaneous (preferred): Into the fat layer via insulin syringe at abdomen, flanks, or thighs. Less painful, consistent absorption.
Intramuscular: Into muscle for faster absorption. More painful; less commonly used in practice.
Duration Guidelines
Short-term (3–6 months): Injury recovery, skin improvement, event-specific goal
Long-term (6+ months): Body composition, anti-aging, hypertrophy
Cycling vs. continuous: Continuous use with low-dose maintenance (1–2 IU) is generally preferred over strict cycling
Monitoring (Every 8–12 Weeks)
Fasting glucose, HbA1c, and fasting insulin
Peptide Interactions
HGH decreases insulin sensitivity and can cause insulin resistance. Diabetics may need increased insulin doses. Monitor blood glucose closely when combining
HGH stimulates endogenous IGF-1 production. Adding exogenous IGF-1 compounds effects but increases hypoglycemia and side effect risks
HGH increases T4 to T3 conversion and can unmask central hypothyroidism in 36-47% of patients. Monitor thyroid function; may require T4 supplementation
GHRH analog that stimulates natural GH release. Can be used with HGH for enhanced effects, though may be redundant if using adequate HGH doses
Ghrelin mimetic that stimulates GH release via different pathway. Combination may enhance overall GH/IGF-1 axis but increases complexity
Growth hormone releasing peptides work synergistically with HGH. Can enhance natural pulsatile release alongside exogenous administration
HGH can unmask cortisol deficiency in hypopituitary patients. Cortisol replacement should precede HGH therapy in patients with multiple deficiencies
Commonly combined in hormone replacement protocols. Both support anabolism, body composition, and well-being. Monitor estrogen conversion
Metformin may be used to manage HGH-induced insulin resistance. Some evidence suggests metformin may reduce IGF-1 levels - monitor response
GLP-1 agonists may help manage HGH-induced insulin resistance while supporting fat loss goals. Increasingly combined in body composition protocols
Reported Research Timeline
01Week 1–2 (reported in cited studies): improved sleep, increased energy, possible water retention
02Month 1–2 (reported in cited studies): fat loss beginning, skin improvement, better recovery
03Month 3–6 (reported in cited studies): significant body composition changes, sustained benefits
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Water retention (puffiness, tight rings): lower dose; reduce sodium; increase potassium; supplement taurine
Joint pain (wrist discomfort): lower dose; glucosamine; B6 (P5P); taurine
Insulin resistance (elevated fasting glucose): switch to night dosing; insulin sensitizers; regular cardio
Headaches (persistent): increase hydration; magnesium; lower dose
Numbness / tingling (extremity tingling): lower dose; B6 (P5P); wrist braces
Do Not Use If:
Active or history of cancer
Active intracranial lesions
Proliferative diabetic retinopathy
Seek Medical Attention If:
Joint, muscle, or nerve pain, or tingling/numbness in extremities (carpal tunnel symptoms)
Severe or persistent headaches or vision changes (possible intracranial pressure)
Rapid weight gain or significant edema (fluid retention)
Always consult a licensed physician — GH therapy requires monitoring of IGF-1 levels
Quality Indicators
Verified Marker
White lyophilized powder
Proper cake/powder appearance, not melted or collapsed
Verified Marker
Crystal clear solution after reconstitution
Must be completely clear with no particles
Quality Concern
Cloudy or discolored
Indicates degradation - do not use
Research Citations
- Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated Patients
Johannsson G, Bidlingmaier M, Biller BMK, et al., 2022, J Clin Endocrinol Metab - Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Molitch ME, Clemmons DR, Malozowski S, et al., 2011, J Clin Endocrinol Metab - Long-term efficacy and safety of somatropin for adult growth hormone deficiency
Götherström G, Bengtsson BÅ, Bosaeus I, et al., 2005, Clin Endocrinol (Oxf) - Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials
Maison P, Griffin S, Nicoue-Beglah M, et al., 2004, J Clin Endocrinol Metab - The interaction between growth hormone and the thyroid axis in hypopituitary patients
Behan LA, Monson JP, Agha A, 2011, Clin Endocrinol (Oxf) - Effects of Growth Hormone on Glucose and Fat Metabolism in Human Subjects
Jørgensen JO, Møller L, Krag M, et al., 2007, Endocrinol Metab Clin North Am - Adult Growth Hormone Deficiency - Benefits, Side Effects, and Risks of Growth Hormone Replacement
Reed ML, Merriam GR, Kargi AY, 2013, Front Endocrinol (Lausanne) - Human growth hormone: 1974-1981
Li CH, 1982, Mol Cell Biochem - Topical Delivery of Cell-Penetrating Peptide-Modified Human Growth Hormone for Enhanced Wound Healing
Nguyen TV, Lee KH, Huang Y, 2023, Pharmaceuticals (Basel) - Thiol-Disulfide Exchange in Human Growth Hormone
Chandrasekhar S, Moorthy BS, Xie R, 2016, Pharm Res - A novel peptide antagonist of the human growth hormone receptor
Basu R, Nahar K, Kulkarni P, 2021, J Biol Chem - Structural variants of human growth hormone: biochemical, genetic, and clinical aspects
Chawla RK, Parks JS, Rudman D, 1983, Annu Rev Med
Research Focus
growthHormone, bodyComposition, antiAging, recovery
Frequently Asked Questions
What should researchers watch for with HGH (Somatropin)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with HGH (Somatropin)?
Week 1–2 (reported in cited studies): improved sleep, increased energy, possible water retention
How is HGH (Somatropin) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →